LXRP - Lexaria Bioscience Granted First European Patent for DehydraTECH(TM) Technology
(TheNewswire)
New patent includes method of treatment claims for a broad range ofdisease conditions including use of:
- cannabinoids to treat cardiac conditions such as hypertension andneurological diseases such as Alzheimer's and Parkinson's
- cannabinoids to treat metabolic disorders and substance abuse andaddictions
- nicotine to treat tobacco dependence/addiction and neurologicaldiseases
- NSAIDs to treat a host of conditions involving pain, fever andinflammatory states
- vitamins to treat conditions such as ataxia related to certainvitamin deficiencies
Kelowna, British Columbia - TheNewswire - October 21, 2020 -Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company"or "Lexaria"), a global innovator in oral drug deliveryplatforms, is pleased to announce that it isreceiving its first-ever granted patent in Europe related to its DehydraTECH TM technology .
European patent number 3164141 will be published in theEuropean Patent Bulletin of November 11, 2020 entitled" Food and BeverageCompositions Infused With Lipophilic Active Agents and Methods of UseThereof " and includes claims for improvedoral delivery of cannabinoids, nicotine, non-steroidalanti-inflammatory drugs (NSAIDs) and vitamins.
In addition, this patent includes important method oftreatment claims for a broad range of disease conditions including useof:
- cannabinoids to treat cardiac conditions such ashypertension and neurological diseases such as Alzheimer's andParkinson's;
- cannabinoids to treat metabolic disorders andsubstance abuse and addictions;
- nicotine to treat tobacco dependence/addiction andneurological diseases;
- NSAIDs to treat a host of conditions involving pain,fever and inflammatory states; and,
- vitamins to treat conditions such as ataxia relatedto certain vitamin deficiencies.
Priority is granted to certain dates in 2014 and 2015,strengthening Lexaria's IP claims compared to more recent competitors. This represents the first patent issuance in Europe under Lexaria'sfirst patent family.
Lexaria intends to validate and nationalize this patentin many major European countries, significantly expanding our globalreach. This patent is a significant addition to the Lexariaintellectual property portfolio, and toward Lexaria's first formalpatent protection across major European nations covering a populationof roughly 340 million people.
"We're very pleased to be awarded our very firstEuropean patent grant as we're continually working to expand both thegeography where Lexaria's intellectual property is protected underlaw, as well as expand the scope of business possible," saidChris Bunka, Lexaria Chief Executive Officer. "The receipt ofthis patent grant is timely in that we have recently forged newrelationships in Europe where a number of countries have veryprogressive markets for the oral delivery of active substancesincluding nicotine and more, supporting our commercializationefforts."
Lexaria currently has 18 granted patents (includingnine granted in the US), along with approximately 60 patentapplications pending throughout the world. The granted patents coverdelivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins.Pending patents are for the delivery of many antiviral drugs, humanhormones such as testosterone and estrogen, phosphodiesteraseinhibitors and more.
About Lexaria
Lexaria Bioscience Corp.'s (OTCQX: LXRP, CSE: LXX)proprietary drug delivery technology, DehydraTECH(TM), improves theway active pharmaceutical ingredients (APIs) enter the bloodstream bypromoting healthier ingestion methods and increasing the effectivenessof fat-soluble active molecules, thereby lowering overall dosing. TheCompany's technology can be applied to many different ingestibleproduct formats, including foods, beverages, oral suspensions,tablets, and capsules. DehydraTECH increases bio-absorption by up to5-10x, reduces time of onset from 1 - 2 hours to minutes, and masksunwanted tastes for orally administered bioactive molecules, includinganti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatorydrugs (NSAIDs), nicotine, and other molecules. Lexaria has licensedDehydraTECH to multiple companies including a world-leading tobaccoproducer for the development of smokeless, oral-based nicotineproducts and for use in industries that produce cannabinoid beverages,edibles, and oral products. Lexaria operates a federally licensedresearch laboratory and holds a robust intellectual property portfoliowith 18 patents granted and approximately 60 patents pendingworldwide. For more information, please visit www.lexariabioscience.com.
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements as suchterm is defined under applicable securities laws. These statements maybe identified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, all statements by the companyrelated to patents granted or pending. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which couldcause actual results to differ materially from those estimated by theCompany include, but are not limited to, government regulation andregulatory approvals, managing and maintaining growth, the effect ofadverse publicity, litigation, competition, scientific discovery, thepatent application and approval process, potential adverse effectsarising from the testing or use of products utilizing the DehydraTECHtechnology, the Company's ability to maintain existing collaborationsand realize the benefits thereof, and other factors which may beidentified from time to time in the Company's public announcements andperiodic filings with the US Securities and Exchange Commission onEDGAR. There is no assurance that existing capital is sufficient forthe Company's needs or that it will be able to raise additionalcapital. There is no assurance the Company will be capable ofdeveloping, marketing, licensing, or selling products containing anyactive ingredient. There is no assurance that any planned corporateactivity, scientific research or study, business venture, letter ofintent, technology licensing pursuit, patent application or allowance,consumer study, or any initiative will be pursued, or if pursued, willbe successful or defensible. There is no assurance that any ofLexaria's postulated uses, benefits, or advantages for the patentedand patent-pending technology will in fact be realized in any manneror in any part. No statement herein has been evaluated by the Food andDrug Administration (FDA). Lexaria-associated products are notintended to diagnose, treat, cure or prevent any disease.
Any forward-looking statements contained in this release speak only asof the date hereof, and the Company expressly disclaims any obligationto update any forward-looking statements contained herein, whether asa result of any new information, future events, changed circumstancesor otherwise, except as otherwise required by law.
The CSE has not reviewed and doesnot accept responsibility for the adequacy or accuracy of thisrelease.
INVESTOR CONTACT:
Phone: 866-221-3341
Copyright (c) 2020 TheNewswire - All rights reserved.